CSL Ltd Research and Development Investor Briefing Transcript
Ladies and gentlemen, good morning, and welcome to CSL's Annual Research & Development Briefing. It's Mark Dehring speaking. And online with me today is Dr. Bill Mezzanotte, Executive Vice President, Head of Research & Development and Chief Medical Officer. He is joined by several of his senior team. Also, joining us once again is Bill Campbell, Executive Vice President and Chief Commercial Officer, CSL Behring. Bill will be providing us with some market insights on CSL Behring's product portfolio.
Please be aware this presentation as well as the Q&A session is being webcast. And lastly, before we start, I draw your attention to the forward statement disclaimer within the slide deck. I'll now hand you over to Bill Mezzanotte. Bill?
Mark, and welcome to all who are joining for the 2022 virtual R&D update. I'm really excited to be hosting today. This is my sixth R&D presentation, fourth
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |